NCT01484600View on ClinicalTrials.gov

Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Healthy
Interventions
DRUG

REGN668: Injection Rate 1

Subjects will receive REGN668 via SC injection

DRUG

REGN668: Injection Rate 2

Subjects will receive study drug via alternate delivery (if necessary)

Trial Locations (1)

78209

San Antonio

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY